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Amyloid precursor protein (APP) intracellular domain (AICD) is a product of APP processing with
transcriptional modulation activity, whose overexpression causes various Alzheimer’s disease (AD)-related
dysfunctions. Here we report that 1-(39,49-dichloro-2-fluoro[1,19-biphenyl]-4-yl)-cyclopropanecarboxylic
acid) (CHF5074), a compound that favorably affects neurodegeneration, neuroinflammation and memory
deficit in transgenic mouse models of AD, interacts with the AICD and impairs its nuclear activity. In
neuroglioma-APPswe cells, CHF5074 shifted APP cleavage fromAb42 to the less toxic Ab38 peptide without
affecting APP-C-terminal fragment, nor APP levels. As revealed by photoaffinity labeling, CHF5074 does
not interact with c-secretase, but binds to the AICD and lowers its nuclear translocation. In vivo treatment
with CHF5074 reduced AICD occupancy as well as histone H3 acetylation levels and transcriptional output
of the AICD-target gene KAI1. The data provide new mechanistic insights on this compound, which is
under clinical investigation for AD treatment/prevention, as well as on the contribution of the AICD to AD
pathology.
T
he main pathological features of Alzheimer disease (AD) are neuronal loss and the presence of neurofi-
brillary tangles together with senile plaques consisting of amyloid beta peptides (Ab40 and Ab42) produced
by cleavage of the amyloid precursor protein (APP) in affected brain regions1,2. APP processing can proceed
through alternative, non-amyloidogenic or amyloidogenic pathways, initiated by either a- or b-secretase cleavage
and leading to the production of two large soluble fragments (sAPPa and sAPPb) and two membrane-anchored
C-terminal fragments, CTFa and CTFb, respectively. CTF processing by c-secretase generates the harmless P3
peptide (non-amyloidogenic pathway) or Ab peptides ranging in size from 35 to 42 amino acids (amyloidogenic
pathway), plus the APP intracellular domain (AICD) fragment3–5. Gamma-secretase is a multisubunit protease
that catalyzes the intramembrane processing of more than 50 type-I membrane proteins6. It is composed of
presenilin (PS1 or PS2), the catalytic subunit responsible for CTF processing, nicastrin (Nct) and the multipass
transmembrane proteins presenilin enhancer 2 (Pen-2) and anterior pharynx-defective 1 (Aph-1)4,5. The amy-
loidogenic pathway has been shown to be the major source of AICD in vivo7,8.
By acting as a docking site for a heterogeneous set of adaptor proteins, the AICD has been shown to be involved
in a variety of signaling processes, many of which are potentially relevant to AD pathology9–11. The best known
AICD interactor is the adaptor protein Fe65, which stabilizes the AICD and promotes its nuclear transloca-
tion3,12,13. In the nucleus, the AICD has been reported to be present within dot-like structures also containing Fe65
and the histone acetyl-transferase Tip6012–14. This multiprotein complex is involved in transcriptional activa-
tion15–17, though the specific role(s) of the AICD in such process, its full set of partner proteins as well as the range
of genes it can target are still debated3,18. The best established AICD target gene codes for the pro-apoptotic
tetraspannin KAI1, also known as CD8214,15,19,20.
AICD and Fe65 overexpressing mice do not show brain Ab accumulation, yet display a number of AD-like
neuropathological features, including tau hyperphosphorylation, glycogen synthase kinase-3b (GSK-3b) activa-
tion, working memory deficits and neuroinflammation9,21. Because AICD levels were found to be elevated in
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human AD brains9,22, it has been hypothesized that this C-terminal
APP fragment may be causally involved in AD pathogenesis9,10,23,24.
However, small-molecules able to bind the AICD and interfere with
its function(s) have not been described so far.
In various transgenicmousemodels of AD, the non-steroidal anti-
inflammatory derivative (NSAID) CHF5074 [1-(39,49-dichloro-2-
fluoro[1,19-biphenyl]-4-yl)-cyclopropanecarboxylic acid] (Fig. 1a)
has been found to lower plaque burden25, tau hyperphosphorylation
and GSK-3b levels26, and to reduce neuroinflammation and assoc-
iated memory deficit25,27,28, thus acting simultaneously on multiple
therapeutic AD targets. CHF5074 has also been shown to improve
cognition and to reduce brain inflammation in ApoE4 patients with
mild cognitive impairment (MCI)29. Similar to other NSAIDs,
CHF5074 modulates c-secretase activity in vitro30, although this
modulatory action does not translate into a measurable effect on
cerebrospinal fluid (CSF) Ab levels in humans31.
Starting from the observation that CHF5074 lowered nuclear
AICD levels in neuroglioma cells expressing the Swedish mutated
form of human APP (H4swe) without inhibiting, but rather modu-
lating, c-secretase activity, we investigated the interaction of
CHF5074 with the APP substrate and the c-secretase enzyme. As
revealed by photoaffinity labeling studies, CHF5074 targets the
AICD region of APP-CTF without any detectable interaction with
c-secretase. In addition to a lowered AICD nuclear translocation in
H4swe cells, CHF5074 treatment of transgenic mice overexpressing
the Swedish mutated form of human APP also markedly reduced
AICDbinding andH3 acetylation levels at the promoter region of the
AICD target gene KAI1, with a concomitant reduction of its tran-
scriptional output. By demonstrating for the first time the targeting
of the AICD region of APP by a small-molecule compound, the data
suggest a plausible mechanism that might contribute to, and explain,
the broad-spectrum neuroprotective properties of CHF5074.
Results
CHF5074 reduces nuclear AICD levels in H4swe cells without
inhibiting c-secretase activity. H4swe cells are a human neuro-
glioma cell line producing the same K595N/M596L mutated form
of APP expressed by the Tg2576 mouse model of AD that has been
extensively utilized for the preclinical characterization of CHF-
507425,27,28,30,32,33. To evaluate whether CHF5074, at concentrations
(1–10 mM) that inhibit Ab42 generation (see Supplementary Fig.
S1a)30, can interfere with the nuclear translocation of the AICD, we
examined AICD levels in nuclear extracts from treated and untreated
H4swe cells. As shown in Fig. 1b (and Supplementary Fig. S2), a
single band corresponding to AICD fragment was revealed by anti-
APP C-terminus antibody. An 18 hour treatment caused a decrease
of AICD nuclear levels, which were reduced by 60% at a CHF5074
concentration of 3 mM. To rule out a possible general inhibitory
effect of CHF5074 on APP-CTF cleavage, that would also nega-
tively affect AICD production, we analyzed APP processing in
H4swe cell extracts with the use of fragment-specific antibodies
recognizing different regions of the APP (see below). We found
that exposure to CHF5074 (1–30 mM) for 18 hours, neither
affected CTFb nor full-length-APP (FL-APP) levels, as detected in
whole cell extracts by immunoblotting with the 6E10 antibody
(Fig. 2a). Similarly, no significant changes were observed in sAPPa
or sAPPb levels by immunoblot analysis of conditioned cell culture
media performed with the anti-APP N-terminal antibody (Fig. 2b
and Supplementary Fig. S3a). As further shown in Fig. 2c (and
Supplementary Fig. S3b), CHF5074 also did not modify neither
CTFa, nor CTFb levels, detected by immunoblot analysis of total
cell extracts with the anti-APP C-terminal antibody (seeMethods for
details). By contrast, a significant increase of both APP-CTFs was
observed under identical experimental conditions upon treatment
with the c-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester) (DAPT; 0.2 mM).
Although the anti-APP C-terminal antibody can also recognize
the AICD, this fragment could not be detected in H4swe whole cell
extracts under standard immunoreaction conditions. Instead, the
AICD was detected in nuclear extracts (see Fig. 1b), in accordance
with previous data indicating that only the AICD produced at the
endosome compartment (i.e., in close proximity to the nuclear com-
partment) can be translocated to the nucleus, thus escaping rapid
cytoplasmic degradation8. Therefore, the unchanged levels of the
APP-CTFs observed in whole extracts from CHF5074-treated cells
(see Fig. 2c) suggest that nuclear translocation, rather than c-secre-
tase-mediated generation of the AICD, is modified by CHF5074
treatment.
Figure 1 | CHF5074 lowers AICD nuclear levels in H4swe cells.
(a) Chemical structure of CHF5074. (b) Immunoblot analysis (anti-APP
C-terminal antibody) of nuclear extracts from H4swe cells treated for
18 hours with vehicle or with different concentrations of CHF5074
(1–10 mM) as indicated. A single polypeptide band immunoreactive to the
anti-APP C-terminal antibody was detected in nuclear templates.
Synthetic AICD-59 polypeptide (7 kDa; shown on the right) was used as a
molecular mass and electrophoretic mobility reference for these
experiments (upper row). Polypeptide band from the same gel was
detected with an anti-histone H3 antibody (lower row). Full-length blots
were presented in Supplementary Figure S2. Data from multiple
experiments are presented as bar plots derived from densitometric
quantification of anti-APP C-terminal antibody immunoreactive bands
(‘‘test’’) normalized with respect to the immunoreactivity signals
(‘‘control’’) produced by the anti-histone H3 antibody. The test/control
ratio for vehicle-treated samples was arbitrarily set to 100%; bars are
the mean 6 s.e.m. of three independent experiments (*, p , 0.05;
***, p , 0.001).
www.nature.com/scientificreports
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In accordance with previous studies30, ELISA analysis of secreted
Ab peptides showed that CHF5074 preferentially inhibits Ab42 com-
pared to Ab40 production. IC50 values were 2.2 mM and 24 mM for
Ab42 andAb40, respectively (Supplementary Fig. S1a).We also found
that the differential effect on Ab40 and Ab42 levels, was accompanied
by an enhanced production of the non-toxic Ab38 peptide. The EC50
for the stimulatory effect of CHF5074 on Ab38 production (2.2 mM)
was identical to that causing half-inhibition of Ab42 secretion. The
resulting curve was bell-shaped and peaked at a 10 mM concentra-
tion of CHF5074 (Supplementary Fig. S1b).
Photoaffinity labeling analysis of the CHF5074-APP interaction.
Photoaffinity labeling studies, using a a photoactivatable benzophenone-
biotin derivative of CHF5074 (CHF5074-BpB; Fig. 3a), were then
carried out to investigate the interaction of CHF5074 with APP-CTF
and the multiprotein c-secretase complex.
As a prerequisite for this analysis, we first verified the functionality
of chemically modified CHF5074-BpB. As shown in Fig. 3, the c-
secretase modulation activity of CHF5074-BpB resembles that of the
parent compound (see also Supplementary Fig. S1a and S1b).
Compared to CHF5074, CHF5074-BpB was somewhat more potent
in reducing Ab42 than Ab40 generation (Fig. 3b), but retained a
similar capacity to enhance Ab38 production (Fig. 3c). Likewise,
CHF5074-BpB did not modify the cellular levels of neither the
CTFs, nor FL-APP (Fig. 3d and Supplementary Fig. S4), and even
at high concentrations (up to 100 mM) it did not appreciably affect
cell viability (Fig. 3e).
We thus proceeded with in vitro photolabeling by incubating
H4swe membrane protein fractions in the presence of CHF5074-
BpB (3 mM), followed by streptavidin-mediated precipitation and
immunoblot analysis using the 6E10 antibody. As shown in Fig. 4a
(and Supplementary Fig. S5a), CHF5074-BpB-cross-linked proteins
bound by steptavidin beads, included FL-APP and the CTFb frag-
ment. A lower immune-signal, especially for FL-APP, was observed
when labeling was performed on whole cell lysates rather than on
membrane fractions (Fig. 4a). With both samples APP-CTF dis-
played a higher reactivity, which was significantly quenched
(,60%) by preincubation with a 33-fold molar excess of unmodified
CHF5074 (Fig. 4b and Supplementary Fig. S5b, cf. the two right-most
lanes). Importantly, parallel photolabeling/immunoblot experiments
performed on H4swe membranes under both denaturing (1%
Nonidet-P40 - NP40) and native conditions, using antibodies target-
ing four c-secretase subunits (PS1, PS2, Nct and Pen-2) did not reveal
any interaction between CHF5074-BpB and the c-secretase enzyme
complex (Fig. 4c).
CHF5074 binds to the intracellular domain of APP. To gain more
detailed information on the APP binding site of CHF5074, we
examined CHF5074-BpB reactivity with two synthetic polypep-
tides corresponding to the Ab42 and AICD-59 fragments of APP
Figure 2 | APP processing in CHF5074-treated H4swe cells. (a) Immunoblot analysis of whole extracts from H4swe cells treated for 18 hours with
vehicle or different concentrations of CHF5074 (1–30 mM). CTFb and FL-APP, whose levels did not appreciably change upon treatment with CHF5074,
were detected with the 6E10 antibody; GAPDH,measured in the same blot with an anti-GAPDH antibody, was used as a loading control. (b) Immunoblot
analysis as in (a) performed with the anti-APP N-terminal antibody in culture medium of H4swe cells treated for 18 hours with vehicle or different
concentration of CHF5074 (1-30 mM). Similar sAPP fragment levels were detected in all samples regardless of CHF5074 treatment. sAPP fragments in the
mediumwere normalized to the actin content detected in the corresponding releasing cells. Full-length blots were presented in Supplementary Figure S3a
c) Immunoblot analysis, performed with the anti-APP C-terminal antibody of extracts from H4swe cells treated with vehicle, CHF5074 (1–30 mM) or
DAPT (0.2 mM) for 18 hours. DAPT, but not CHF5074, increases CTFa and b levels (*, p, 0.05). Full-length blots were presented in Supplementary
Figure S3b. Bar plots, shown below each gel image, were obtained by densitometric analysis of immunoblot data normalized with respect to the
immunoreactivity signals detected by control antibodies (GAPDH, panel a; actin, panels b and c). The test/control ratio for vehicle-treated samples was set
to 1.0; bars represent the mean 6 s.e.m. of three independent experiments.
www.nature.com/scientificreports
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and with a recombinant glutathione S-transferase-CTFa (GST-
CTFa) fusion polypeptide (see Fig. 5a). Each polypeptide (20 pmol)
was individually incubated with CHF5074-BpB (3 mM), alone and in
the presence of an excess of unmodified CHF5074. As shown in
Fig. 5b (upper panels), both AICD-59 and GST-CTFa, but neither
Ab42 peptide, nor the GST carrier protein alone, were detected with
IrDye-labeled streptavidin following treatment with CHF5074-BpB
and the resulting signals were both quenched (,30% and 70%,
respectively) by addition of the unmodified compound. Compara-
ble results in terms of photolabeling selectivity were obtained with
CHF5074-BpB concentrations as low as 0.5 mM (data not shown)
and a similar lack of CHF5074-BpB reactivity with Ab was observed
with monomeric (Fig. 5b), as well as oligomeric (Supplementary Fig.
S6) Ab42. Altogether, the above results point to the specific binding
of CHF5074 to the AICD, a C-terminal region of APP downstream
to the cleavage site of c-secretase.
In vivo treatment with CHF5074 reduces AICD occupancy, his-
tone acetylation levels and transcriptional activity of an AICD
target gene. We next evaluated whether CHF5074, in addition to
its lowering effect on nuclear AICD levels in a cell-based model of
AD (Fig. 1b), could also affect nuclear AICD functionality and target
gene promoter occupancy in vivo. To this end, we performed a
chromatin immunoprecipitation (ChIP) analysis on brain cortices
from Tg2576 mice treated with either CHF5074-supplemented diet
(375 ppm;<60 mg/kg/day) or standard diet for 4 weeks. The choice
of this treatment protocol was based on previous preclinical data
showing full reversal of recognition memory and a marked amelio-
ration of various AD-related neuropathological features, in Tg2576
mice orally treated with the same dose of CHF5074 for 4 weeks32.
The tetraspanin-encoding KAI1 gene, a broadly supported AICD-
target14,15,20 previously subjected also to ChIP analysis15,20, was used to
test the effect of CHF5074 treatment. To this end, cross-linked
chromatin from brain cortices of treated and untreated animals
was separately immunoprecipitated with the anti-APP C-terminal
antibody, an anti-acetylated histone H3 antibody, and an unrelated,
control antibody. As revealed by quantitative RealTime-PCR analy-
sis of immunoprecipitated DNA (Fig. 6a), treatment with CHF5074
Figure 3 | The photoactivatable CHF5074-BpB derivative retains the c-secretase modulatory properties of the parent compound. (a) Chemical
structure of the benzophenone-biotin (BpB) derivative of CHF5074, whose synthesis is described in Supplementary Methods. Similar to the parent
compound, CHF5074-BpB reducedAb40 andAb42 secretion (b) and increased Ab38 production (cf. data reported in Supplementary Fig. S1a and S1b) (c).
Ab peptide release was evaluated by ELISAs performed on conditioned culture media from H4swe cells exposed to the indicated concentrations of
CHF5074-BpB (0.1–100 mM) for 18 hours. Data are percentages of control 6 s.e.m. from three independent experiments. (d) Representative results
obtained from immunoblot analysis (anti-APP C-terminus and control anti-actin antibodies as in Fig. 2c) of extracts from H4swe cells treated with
vehicle or CHF5074-BpB (1–100 mM). Full-length blots were presented in Supplementary Figure S4. (e) Cell viability, assayed with the lactate
dehydrogenase (LDH) release assay, was not appreciably affected by CHF5074-BpB at any of the tested concentrations; data are presented as percentages
of control 6 s.e.m. from three independent experiments.
www.nature.com/scientificreports
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was associated to an 79% reduction of AICD occupancy and an 72%
decrease of histone H3 acetylation at the KAI1 promoter. As further
shown in Fig. 6b, these changes were accompanied by a significant
reduction of KAI1 transcripts. These data suggest that, in addition to
nuclear translocation, CHF5074 binding to the AICD interferes with
nuclear transactions (i.e., promoter binding, recruitment of histone
acetyl-transferase components such as Tip60 and target gene
transcriptional output) mediated by the intracellular C-terminal
fragment of APP.
Discussion
The main finding of this study is the peculiar ability of the anti-
inflammatory derivative CHF5074 to reduce nuclear translocation
and activity of the APP intracellular domain by binding to the AICD
peptide without altering its c-secretase-mediated generation.
In accordance with previous data30, CHF5074 preferentially re-
duced Ab42, compared to Ab40, levels and increased production of
the non-toxic Ab38 peptide in H4swe neuroglioma cells, the cellular
counterpart of the Tg2576 mouse model of AD. This suggests that
CHF5074 does not inhibit APP processing, but rather shifts the site
of APP-CTF cleavage. Indeed, CHF5074 did not increase APP-CTF
levels, as observed with the c-secretase inhibitor DAPT (Fig. 2c; but
see also34), and neither affected soluble APP fragment levels, nor the
levels of FL-APP, indicating the lack of any effect on a-secretase or b-
secretase activity.
Using a photoaffinity labeling approach, we found that CHF5074
binds to the AICD region of the APP-CTF substrate, but not to the c-
secretase complex. Binding selectivity was inferred from competition
of unmodified CHF5074 on the binding of CHF5074-BpB to the
AICD, which took place at concentrations 30- to 100-fold lower than
those employed for photoaffinity labeling with BpB derivatives of 1st
generation c-secretase modulators35. In line with recent models for
sequential cleavage by c-secretase36,37, we hypothesize that CHF5074
binding to the AICD region of APP may influence c-secretase pro-
cessivity by altering the dynamics and/or the stereochemistry of
interaction between the enzyme and its substrate.
CHF5074 lowered AICD occupancy, H3 acetylation levels and
transcriptional output of the target gene KAI1, suggesting that
CHF5074 binding interferes not only with the nuclear translocation,
but also with the nuclear activity (i.e., promoter binding and
co-activator recruitment) of the AICD. The KAI1 gene codes for a
proapototic tetraspanin and is one of the best established AICD
targets14,15,19,20. Indeed, neuronal apoptosis is considered a common
feature of AD and the first cellular alteration that was shown to be
positively regulated by the AICD22,38; an alteration that could be
prevented by blocking AICD nuclear translocation38 as well as by
artificially weakening the AICD-Fe65 interaction17.
Given the reduction of nuclear AICD levels brought about by
CHF5074 and the well-known AICD-stabilizing effect of the Fe65
adaptor (reviewed by3,23), it is tempting to speculate that CHF5074
binding to APP-CTF may hinder the AICD-Fe65 interaction. This
would promote cytoplasmic instability and a reduced nuclear trans-
location of the AICD, ultimately leading to a decreased promoter
occupancy. Other, not mutually exclusive hypotheses are also pos-
sible, however. For example, interference of CHF5074 with the APP-
CTF-Fe65 interaction might be sufficient to enhance cytoplasmic
AICD degradation and to lower the nuclear translocation/activity
of Fe6539. The same interaction, which involves the YENPTY region
of the AICD (aa. 682–687), has been reported to promote the amy-
loidogenic pathway thus increasing Ab production, an effect that
could be blocked bymutation (Y682G) of the AICDTyr682 residue40
as well as by artificial silencing of Fe6541. Furthermore, reversion of
various neuropathological features of AD, including astrogliosis and
cognitive impairment, has been reported in Tg-AD mice bearing a
D664A mutation in the AICD42.
Also notable is the overlap between the positive effects brought
about by CHF5074 treatment in various transgenic mouse models of
AD25–28,32,43 and the specific AD-related alterations associated with
AICD/Fe65 overproduction. The latter, in addition to tau hyperpho-
sphorylation/aggregation and cognitive impairment9, include an
altered cytoskeleton dynamics44, impaired neurogenesis and neu-
roinflammation21. All the above alterations are reverted to varying
Figure 4 | Photoaffinity labeling analysis of CHF5074-BpB-treated H4swe cells. (a) Photoaffinity labeling of FL-APP and CTFb in membrane fractions
and total lysates from H4swe cells incubated with CHF5074-BpB (3 mM) and exposed to ultraviolet light (350 nm, 30 minutes), prior to streptavidin
precipitation (IP), gel-fractionation and immunoblot analysis with the 6E10 monoclonal antibody. Immunoreactivity of naı¨ve membrane fractions (i.e.,
membranes not treated with CHF5074-BpB and not subjected to streptavidin precipitation) is shown on the right (‘‘start’’). Full-length blots were
presented in Supplementary Figure S5a. (b) Reduced CHF5074-BpB labeling of APP-C-terminal fragments upon preincubation with unmodified
CHF5074 (100 mM). Labeling was performed onmembrane fractions, followed by streptavidin precipitation, gel-fractionation and immunoblot analysis
with the anti-APP C-terminal antibody (see legend to panel a for further details). Specific labeling by CHF5074-BpB was detected over the background
signals observed when omitting the photoprobe (lane 2) or the membranes (lane 3) from the reaction mixture. Full-length blots are presented in
Supplementary Figure S5b. (c) Immunoblot analysis of CHF5074-BpB-treated membranes as in (a), performed with antibodies directed against the
indicated c-secretase subunits: nicastrin, Nct; presenilin-1 N-terminal fragment, PS1-NTF; presenilin-1 C-terminal fragment, PS1-CTF; presenilin-2,
PS2; presenilin enhancer-2, Pen-2 (see legend to panel a for further details). Lack of photolabeling was observed even when the membranes were exposed
to the CHF5074-BpB photoprobe prior to detergent solubilization (‘‘native conditions’’). Cropped blot images (derived from ten different experiments)
were shown.
www.nature.com/scientificreports
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extents and with a high degree of specificity compared to other
NSAIDs, by CHF507425–28,32,43. In addition, recent studies indicate
the ability of CHF5074 to positively affect CSF biomarkers of neu-
roinflammation in MCI subjects29, further suggesting that this com-
pound may also act as a microglial modulator capable of reducing
pro-inflammatory activity, while promoting the alternative anti-
inflammatory and phagocytic state of microglial cells (Porrini et
al., AD/PD Conference 2013).
Despite increasing evidence pointing to a causal relationship
between AICD overproduction and AD, and the fact that increased
AICD levels have been detected in human AD brain9,22, data suggest-
ing a beneficial role of this polypeptide, at least under certain con-
ditions, have also been reported45. Moreover, another strongly
supported AICD target gene, codes for the Ab-degrading enzyme
neprilysin24,46. Therefore, the borderline between physiological and
neuropathological effects of the AICD is likely to be quite narrow and
finely tuned, with a shift toward neuropathology uponmassive accu-
mulation through sustained activation of the amyloidogenic pathway.
In conclusion, the present findings provide an extended mech-
anistic background for the multiple effects of CHF5074. To our
Figure 5 | Photoaffinity labeling analysis of specific APP fragments. (a) Schematic representation of APP processing products, including the binding
sites of the antibodies utilized in this work and the APP fragments that were subjected to photolabeling analysis: the CHF5074-BpB-reactive CTFa and
AICD-59 fragments (black bars) and the non-reactive Ab42 peptide (white bar). (b) Photoaffinity labeling profiles (upper panels) obtained after incubation
with (1) orwithout (2) CHF5074-BpB (3 mM)of the synthetic AICD-59 (20 pmol, left panel) andAb42 (20 and 90 pmol, central panel) peptides, and the
empty glutathione S-transferase carrier (GST) and the recombinant GST-CTFa fusion polypeptide (20 pmol, right panel). CHF5074-BpB reactive
products were detected with IrDye 680-conjugated streptavidin. Labeling competition experiments were performed by preincubating 20 pmol of the
AICD-59 peptide (left panel) or the GST-CTFa fusion polypeptide (right panel) in the presence (1) of unmodified CHF5074 (100 mM), followed by
exposure to 3 mMCHF5074-BpB. Parallel immunoblot analyses performedwith the anti-APPC-terminal antibody (AICD-59), the 6E10 antibody (Ab42)
and with an antibody directed against GST (GST and GST-CTFa), served as controls to verify the input of the various (poly)peptides utilized for these
experiments (lower panels). Cropped gel images are shown and the gels were run under the same experimental conditions.
www.nature.com/scientificreports
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knowledge, CHF5074 is the first AICD-targeting small-molecule to
be described and we believe that the availability of this compound
will contribute to a better understanding of both the physiological
role(s) of the AICD as well as its involvement in AD pathology.
Methods
Cell culture.H4swewere seeded at a density of 1.253 105 cells/cm2 in 21 cm2 culture
dishes (Nunc-VWR) in Opti-MEM culture medium (Life Technologies) containing
10% fetal bovine serum and grown to confluence in a 5%CO2 and 95% air humidified
atmosphere. Cells were then incubated in Opti-MEMwithout serum and exposed for
18 hours to either 0.1–30 mM CHF5074 (Figure 1a), 0.1–100 mM CHF5074-BpB
(Figure 3a) or 0.2 mM DAPT (all provided by Chiesi Farmaceutici, Parma, Italy)
dissolved in dimethyl sulfoxide (DMSO; 0,1% final concentration), or to the DMSO
vehicle alone. The culture mediumwas collected and used for ELISA and cytotoxicity
assays, followed by membrane and nuclear protein extraction for immunoblot/
photoaffinity labeling.
Ab measurements in H4swe culture medium. H4swe cells were exposed for
18 hours to increasing concentrations of CHF5074 (0.1–30 mM) or CHF5074-BpB
(0.1–100 mM) in culture mediumwithout serum. At the end of treatment, Ab40, Ab42
and Ab38 were measured in a fixed volume (25 ml) of culture medium supplemented
with protease inhibitors (Sigma-Aldrich). Ab40 andAb42 levels in the culturemedium
were determined with commercial ELISA kits (Life Technologies). A modification of
the ELISA kit for Ab40 was used to measure Ab38 levels. A monoclonal antibody
specific for the N-terminus of human Ab was coated onto the wells of microtiter
strips. Culture medium samples were then incubated with a rabbit antibody specific
for the C-termini of the 1–40, 1–42 and 1–38 Ab peptides (Covance), followed by
detection of bound antibodies with a horseradish peroxidase (HRP)-conjugated anti-
rabbit antibody.
Extract preparation and immunoblot analysis.H4swe cells were harvested in 100 ml
of lysis buffer, sonicated for 30 seconds at full power (SONOPULS, titaniummicrotip
MS-72) and centrifuged at 11,000 g for 20 minutes at 4uC. Total extracts (25 mg total
protein/sample) or 25 ml of culture medium were dissolved in sample buffer and
fractionated by electrophoresis on 4–12% gradient polyacrylamide-SDS gels. The
anti-APP (Ab amino acids 1–16) monoclonal antibody 6E10 (SIG-39320, Covance),
an anti-APP C-terminus (A8717, Sigma-Aldrich) or an anti-APP N-terminus (14-
6132 eBioscience) antibody were used for detection. Antiglyceraldehyde 3-phosphate
dehydrogenase (GAPDH - MAB374, Millipore), anti-b-actin (A5060, Sigma-
Aldrich) and anti-histone H3 (9715, Cell Signaling Technology, CST) antibodies
served as loading controls.
For nuclear protein isolation, H4swe cells were scraped into 1.5 ml of ice-cold
phosphate buffered saline (PBS). Cells were pelleted and resuspended in ice-cold
buffer A [10 mM HEPES-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride - PMSF]. Cells were allowed to
swell on ice for 10 minutes, vortexed for 10 seconds and centrifuged (18,000 g, 1
minute at 4uC). The pellet was resuspended in ice-cold buffer B (20 mM HEPES-
KOH pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
dithiothreitol, 0.2 mM PMSF) and incubated on ice for 20 minutes for high-salt
extraction. Cellular debris was removed by centrifugation (18,000 g, 2 minutes at
4uC) and the supernatant was stored at280uC. Immunoblot analysis of theAICDwas
performed according to47 using the anti-APP C-terminal antibody; the synthetic
AICD-59 peptide (#018-710, Phoenix Pharmaceuticals) served as a size reference and
positive control for these experiments.
Cell membrane isolation.H4swe cells from a confluent 10 cm dish were collected in
500 ml of protease/phosphatase inhibitors-supplemented, ice-cold buffer C (320 mM
sucrose, 1 mM HEPES, 1 mM MgCl2, 10 mM NaHCO3, pH 7.4) and sonicated.
Homogenates were centrifuged at 13,000 g for 15minutes andmembrane-containing
pellets were resuspended in 300 ml of ice-cold buffer D (50 mM NaCl, 30 mM
triethanolamine, 50 mM NaF, 5 mM EGTA, 5 mM EDTA, 10 mM phospho-
nitrophenylphosphate, 50 mM phenylarsine-oxide, 1 mM benzamide, 1 mM N-
ethylmaleimide, 1 mM Na-tetrathionate, 1% NP40). Membrane fractions for
c-secretase analysis were also prepared under native conditions48 by omitting the Brij-
35/Lubrol WX extraction step, diluted three-fold with protease inhibitor-
supplemented resuspension buffer (66.7 mM e-aminocaproic acid, 1 mM EDTA,
10 mMDTT and 50 mMBisTris-HCl, pH 7.0) and cross-linked with the photoprobe
prior to detergent (NP-40) solubilization.
Photoaffinity labeling with CHF5074-BpB.Total cell lysates ormembrane fractions
(50 mg total protein/sample) were pre-incubated for 15 minutes at 37uC in the dark
with CHF5074-BpB (3 mM; see Supplementary Methods) and then exposed to
ultraviolet light (350 nm) for 30 minutes as described35. For competition
experiments, membrane fractions were preincubated for 15 minutes with the parent
compound (100 mM) prior to the addition of CHF5074-BpB. Labeled samples were
analyzed by SDS-PAGE after precipitation with streptavidin magnetic beads
(Thermo Fisher Scientific). After blotting and antibody reaction (6E10 mAb 15250
for full-length APP and APP-CTFb; anti-APP C-terminal antibody 15200 for APP-
CTFa and b), immunoreactive proteins were detected by HRP chemiluminescence
(ECL-Plus, GE-Healthcare). Gamma-secretase subunits were detected with anti-
nicastrin (151,000; Cell Signaling Technology); anti-PS1 N-terminus (15250; Santa
Cruz Biotechnology) and C-terminus (151,000; CST); anti-PS2 (151,000; CST); and
anti-Pen2 (diluted 151,000; CST) antibodies.
Photoaffinity labeling of isolated peptides was carried out by incubating CHF5074-
BpB (3 mM), directly or after preincubation in the presence of the parent compound
(100 mM), with 20 pmol of AICD-59 (Phoenix Pharmaceuticals) and Ab42
(EZBiolab) as well as with equimolar amounts of the recombinant CTFa polypeptide
(83 aa.). The latter was produced in Escherichia coli as a fusion protein with glu-
tathione S-transferase (GST) (pGEX-4T-2 vector; GE-Healthcare) and purified/
solubilized from bacterial lysates as described49. After photolabeling in 50 mMMES,
0.1 M NaCl, pH 6.0 as described above, CHF5074-BpB-treated samples were frac-
tionated by SDS-PAGE on Criterion TGX-AnykD polyacrylamide gels (BioRad) and
transferred to nitrocellulose membranes by electroblotting. Following heating at
100uC in PBS for 25 seconds, membranes were blocked with 5% bovine serum
albumin (BSA) in tris-buffered saline (TBS) and incubated with IrDye 680 strepta-
vidin (diluted 153,000; LI-COR). Biotin-labeled polypeptides were visualized by near-
infrared fluorescence with an Odyssey imager as described32. The polypeptide input
was verified in each experiment by parallel analysis of the same samples with either a
rabbit anti-APP C-terminus antibody (for AICD-59), the 6E10 mAb (for Ab42), or a
rabbit anti-GST antibody (for GST-CTFa and GST).
Chromatin Immunoprecipitation assays. Chromatin immunoprecipitation (ChIP)
assays were performed with the Magna ChIP Tissue kit (#17-20000, Millipore). Ten-
month-old Tg2576 female mice (Taconic), fed with CHF5074-supplemented
(375 ppm) or standard diet (n5 6 animals/group) were employed for these analyses.
Animal care and treatments were in accordance with European Community Council
directives (86/609/EEC) and in conformity with protocols approved by ethical
committee for animal experimentation of University of Bologna.
Following sacrifice and brain dissection, three randomly assorted pools of
entorhinal cortices from each group were frozen and chopped into small pieces.
Figure 6 | Effect of in vivo CHF5074 treatment on AICD occupancy, histone H3 acetylation and transcriptional activity of the KAI1 gene.
(a) Chromatin immunoprecipitation assays performed on brain cortices from Tg2576 mice treated for 4 weeks with standard (black bars) or CHF5074-
supplemented diet (375 ppm;<60 mg/kg/day;white bars) using anti-APP C-terminus and anti-acetyl H3 as test antibodies and an anti-IgG as a negative
control antibody. DNA extracted from immunoprecipitated chromatin was analyzed by qRT-PCR, setting CT values relative to untreated samples to 1.0
(see ‘Methods’ for details). (b) KAI1 mRNA levels determined by qRT-PCR analysis of reverse-transcribed total RNA extracted from brain cortices of
Tg2576 mice fed on standard (black bars) and CHF5074-supplemented (white bars) diet as above. Data are presented as relative values determined with
the comparative CT method using b-actin as house-keeping gene reference; bars are the mean 6 s.e.m. of three independent experiments (**, p, 0.01).
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Minced tissue was cross-linked with 1.5% formaldehyde for 10 minutes at 37uC and
subsequently incubated for 5 min in a 0.15 M glycine solution to stop the reaction.
Cross-linked tissue was washedwith ice-cold PBS and incubated on ice for 15minutes
in Tissue Lysis Buffer. Nuclei were then pelleted (800 g, 5 minutes at 4uC), resus-
pended in Dilution Buffer and sonicated. After centrifugation, aliquots of each
chromatin sample were separately incubated with anti-APP C-terminus, anti-acetyl
H3 (#07-593; Millipore) or anti-IgG (negative control) antibodies. Magnetic protein
G beads were then added, followed by overnight incubation at 4uC on a rotating
wheel. Another chromatin sample, not incubated with any antibody, served as input
control. Antibody-captured protein/DNA complexes were washed, eluted and sub-
jected to quantitative real-time polymerase chain reaction (qRT-PCR) analysis with
the following forward (Fw) and reverse (Rev) primers: KAI1-Fw 59-ATCATG-
CCATGCTGTCTGTC-39; KAI1-Rev 59-GGGCATAGGGTAGGCTGAG-39.
Immunoprecipitated DNA (2 ml/sample) was amplified in a 25 ml reactionmixture
containing the SYBRGreenmaster mix (BioRad). Real-time PCR analysis was carried
out in triplicate using an iCycler (BioRad) apparatus. CT values generated by qRT-
PCR analysis of samples immunoprecipitated with the anti-APP C-terminus or anti-
acetyl-H3 antibodies were first normalized with respect to the corresponding CT
values obtained from IgG-immunoprecipitated, negative control samples, and then
with respect to the relative CT values obtained from ‘‘input’’ (i.e., ‘‘no antibody’’)
chromatin samples.
Transcript level determinations. Total RNA was extracted from mouse entorhinal
cortices of Tg2576 mice treated with CHF5074-supplemented or standard diet as
described above (n 5 3 animals/group) using the RNeasy Lipid Tissue Mini Kit
(Qiagen, # 74804). RNA (1 mg/sample) was reverse-transcribed with the QuantitectH
Reverse Transcription Kit (Qiagen, # 205313), using an optimized mix of oligo-dT,
random primers and primer plus 73 gDNAWipeout Buffer, and incubated at 42uC
for 2 minutes to remove contaminating genomic DNA. 53 Quantiscript RT Buffer,
Quantiscript Reverse Transcriptase and RT Primer Mix were then added and the
reaction mixture was incubated at 42uC for 15 minutes, followed by thermal
inactivation at 95uC for 3 minutes.
After cDNA synthesis, RT-PCR was carried out as described above, using the
following KAI1 gene-specific primers (0.3 pmol/mL): Fw 59-TTACGTCTTCATC-
GGTGTGG-39; Rev 59- CACTGTGTTCCCCATCTCCT-39. The comparative CT
methodwas used for relativemRNAquantification;b-actin, amplified with the Fw 59-
GGCTCTTTTCCAGCCTTCCT-39 and Rev 59- ATGCCTGGGTACATGGTGGT-
39 primers, was used for expression level normalization.
Statistical analysis. Statistical significance of differences between groups was
evaluated by two-way ANOVA and Dunnet’s multiple comparison tests using the
GraphPad Prism 5 software (GraphPad Software, La Jolla, CA, USA). ChIP data were
analyzed with Student’s t-tests for independent data. P-values (p) lower than 0.05
were considered as statistically significant.
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